ADMA Biologics, Inc. (ADMA)

NASDAQ: ADMA · Real-Time Price · USD

8.27

-0.10 (-1.19%)

At close: Jul 24, 2026, 4:00 PM EDT

8.22

-0.05 (-0.58%)

After-hours: Jul 24, 2026, 7:46 PM EDT

ADMA Biologics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	509.86	510.17	426.45	258.22	154.08	80.94
Revenue Growth	10.99%	19.63%	65.16%	67.58%	90.36%	91.72%
Gross Profit	312.42	292.77	219.55	88.94	35.27	1.17
Operating Income	214.84	191.44	138.98	21.63	-39.37	-58.37
Net Income	165.35	146.93	197.67	-28.24	-65.9	-71.65
Earnings Per Share	0.68	0.60	0.81	-0.13	-0.33	-0.51
EPS Growth	-20.00%	-25.93%	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
ADMA BioManufacturing	493.03	493	415.81	249.74	144.07	74.94
Plasma Collection Centers	-	17.03	10.51	8.33	9.87	5.86
License	0.14	0.14	0.14	0.14	0.14	0.14
Revenue (Total)	509.86	510.17	426.45	258.22	154.08	80.94

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	138.15	87.63	103.15	51.35	86.52	51.09
Total Debt	204.41	79.89	83.43	143.11	155.94	102.92
Net Cash (Debt)	-66.25	7.75	19.72	-91.75	-69.42	-51.83
Net Cash Growth	-	-60.72%	-	-	-	-
Net Cash Per Share	-0.27	0.03	0.08	-0.41	-0.35	-0.37

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	128.32	50.4	118.67	8.8	-59.51	-112.37
Capital Expenditures	-20.42	-22.58	-8.23	-4.77	-13.91	-13.51
Free Cash Flow	107.9	27.82	110.45	4.03	-73.42	-125.88
Free Cash Flow Growth	19.05%	-74.81%	2641.28%	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	61.27%	57.39%	51.48%	34.44%	22.89%	1.45%
Operating Margin	42.14%	37.53%	32.59%	8.38%	-25.55%	-72.12%
Pretax Margin	40.47%	35.80%	29.48%	-10.94%	-42.77%	-104.92%
Profit Margin	32.43%	28.80%	46.35%	-10.94%	-42.77%	-104.92%
FCF Margin	21.16%	5.45%	25.90%	1.56%	-47.65%	-155.52%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 25, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	12.17	30.40	21.17	-	-	-
Forward PE	9.96	22.24	25.28	36.16	-	-
P/FCF Ratio	17.76	155.96	36.74	253.61	-	-
PS Ratio	3.76	8.50	9.52	3.96	5.59	3.41